Literature DB >> 36267128

Selective Cyclin-Dependent Kinase Inhibitors and Their Application in Cancer Therapy.

Robert B Kargbo1.   

Abstract

Every cell cycle step is a well-regulated process controlled by cyclin-dependent kinases (CDKs). Selectivity to individual CDKs is crucial in minimizing potential off target complications. Disclosures in this Patent Highlight provides CDK2-selective inhibitor compounds and methods for treating cancers. Published 2022 by American Chemical Society.

Entities:  

Year:  2022        PMID： 36267128      PMCID： PMC9578029          DOI： 10.1021/acsmedchemlett.2c00417

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.632


  6 in total

Review 1.  From Structure Modification to Drug Launch: A Systematic Review of the Ongoing Development of Cyclin-Dependent Kinase Inhibitors for Multiple Cancer Therapy.

Authors:  Zhenfeng Shi; Lei Tian; Taotao Qiang; Jingyi Li; Yue Xing; Xiaodong Ren; Chang Liu; Chengyuan Liang
Journal:  J Med Chem       Date:  2022-04-29       Impact factor: 7.446

Review 2.  Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts.

Authors:  Zhouling Xie; Shuzeng Hou; Xiaoxiao Yang; Yajun Duan; Jihong Han; Qin Wang; Chenzhong Liao
Journal:  J Med Chem       Date:  2022-03-02       Impact factor: 7.446

3.  Development of Dual Inhibitors Targeting Epidermal Growth Factor Receptor in Cancer Therapy.

Authors:  Lun Tan; Jifa Zhang; Yuxi Wang; Xiye Wang; Yanyan Wang; Zhixiong Zhang; Wen Shuai; Guan Wang; Juncheng Chen; Chengdi Wang; Liang Ouyang; Weimin Li
Journal:  J Med Chem       Date:  2022-03-21       Impact factor: 7.446

Review 4.  Advances in Pyrazole Based Scaffold as Cyclin-dependent Kinase 2 Inhibitors for the Treatment of Cancer.

Authors:  Jahara Shaikh; Kavitkumar Patel; Tabassum Khan
Journal:  Mini Rev Med Chem       Date:  2022       Impact factor: 3.862

Review 5.  Targeting CDK4 and CDK6 in cancer.

Authors:  Shom Goel; Johann S Bergholz; Jean J Zhao
Journal:  Nat Rev Cancer       Date:  2022-03-18       Impact factor: 69.800

Review 6.  Transcriptional cyclin-dependent kinases: Potential drug targets in cancer therapy.

Authors:  Yi Liu; Leilei Fu; Junhao Wu; Ming Liu; Guan Wang; Bo Liu; Lan Zhang
Journal:  Eur J Med Chem       Date:  2021-12-16       Impact factor: 6.514
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.